Can roselixizumab not be stopped once it is started?

Whether Rozanolixizumab must be continued? The answer varies depending on the patient's condition. Rozelixizumab can effectively alleviate the immune-mediated damage of myasthenia gravis (a rare disease) by reducing the level of pathogenic IgG. However, it is not a radical treatment drug, so the treatment principle focuses on symptom management and improvement of quality of life.

In the early stages of treatment, patients generally complete a full course of treatment for 6 weeks. Doctors will comprehensively evaluate the next treatment strategy based on efficacy and tolerability. For most patients, significant improvement in muscle strength can be observed after the first course of treatment, and the condition becomes stable. At this time, individual decision-making is required as to whether to continue taking medication. Some patients are in good and stable condition after a course of treatment. Doctors may recommend intermittent medication and enter an observation period. At the same time, regular follow-up visits are arranged to monitor changes in muscle strength and antibodies to avoid the risk of long-term immunosuppression caused by unnecessary medication.

However, myasthenia gravis is an autoimmune disease characterized by recurrent attacks and chronic fluctuations. Discontinuation of the drug may lead to the gradual recovery of the pathogenicIgG levels and the patient's symptoms to reappear or worsen. Therefore, for patients with more severe conditions or who are prone to relapse, maintenance therapy is often recommended to maintain sustained remission and avoid frequent attacks that cause a significant decrease in quality of life. Maintenance treatment can be achieved through periodic repeated treatment courses, and the intervals are adjusted according to the patient's specific conditions to avoid side effects caused by excessive frequent medication.

It is worth noting that the safety of rozelixizumab is good, but the long-term immunomodulatory effect still requires attention to the risk of infection and potential impact on immune function. Doctors usually adjust the frequency and dosage of medication based on the patient's immune status, concomitant diseases, and drug reactions. For some patients with drug resistance or significant side effects, alternative treatments or adjuvant supportive therapies may need to be considered.

Reference materials:https://www.drugs.com/rystiggo.html